









Markets
/
Stocks
/
nasdaq-mgtx
/

MeiraGTx Holdings PLC

MGTX

7.990USD

+0.660+9.00%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

642.77MMarket Cap

LossP/E TTM



MeiraGTx Holdings PLC

7.990

+0.660+9.00%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

83 / 506

Overall Ranking

188 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

27.333

Target Price

+272.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 109.04% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 33.28M.

Undervalued

The company’s latest PE is -3.94, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 67.71M shares, increasing 5.70% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 420.67K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.18.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 5.44, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 3.69M, representing a year-over-year increase of 1208.87%, while its net profit experienced a year-over-year increase of 20.21%.

Score

Industry at a Glance

Previous score

5.44

Change



Financials

4.53

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.78

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.05

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -3.61, which is -31.91% below the recent high of -2.46 and -1.56% above the recent low of -3.67.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 83/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.33, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for MeiraGTx Holdings PLC is 26.50, with a high of 50.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

27.333

Target Price

+272.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

MeiraGTx Holdings PLC

MGTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.51, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 7.91 and the support level at 6.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.51

Change

2.39

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.051

Neutral

RSI(14)

58.183

Neutral

STOCH(KDJ)(9,3,3)

58.947

Buy

ATR(14)

0.382

Low Volatility

CCI(14)

145.246

Buy

Williams %R

7.182

Overbought

TRIX(12,20)

-0.195

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

7.516

Buy

MA10

7.555

Buy

MA20

7.545

Buy

MA50

7.923

Buy

MA100

7.030

Buy

MA200

6.732

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 84.26%, representing a quarter-over-quarter decrease of 15.62%. The largest institutional shareholder is The Vanguard, holding a total of 420.67K shares, representing 0.52% of shares outstanding, with 10.68% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

12.58M

Sanofi SA

12.20M

Johnson & Johnson Innovation-JJDC, Inc.

6.64M

Adage Capital Management, L.P.

5.63M

+11.92%

Prosight Capital

3.69M

-15.93%

Rubric Capital Management LP

1.78M

Adena Estate Inc.

3.27M

683 Capital Management LLC

2.58M

+6.63%

BlackRock Institutional Trust Company, N.A.

2.73M

+3.32%

J. Goldman & Co., L.P.

1.16M

+110.48%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.91, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.33. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.